MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines
Related Experiment Video
Updated: Aug 1, 2026

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Abstract:
A candidate tumor suppressor gene, MMAC1/PTEN, located in human chromosome band 10q23, was recently identified based on sequence alterations observed in several glioma, breast, prostate, and kidney tumor specimens or cell lines. To further investigate the mutational profile of this gene in human cancers, we examined a large set of human tumor specimens and cancer cell lines of many types for 10q23 allelic losses and MMAC1 sequence alterations. Loss of heterozygosity (LOH) at the MMAC1 locus was observed in approximately one-half of the samples examined, consistent with the high frequency of 10q allelic loss reported for many cancers. Of 124 tumor specimens exhibiting LOH that have been screened for MMAC1 alterations to date, we have detected variants in 13 (approximately 10%) of these primary tumors; the highest frequency of variants was found in glioblastoma specimens (approximately 23%). Novel alterations identified in this gene include a missense variant in a melanoma sample and a splicing variant and a nonsense mutation in pediatric glioblastomas. Of 76 tumor cell lines prescreened for probable LOH, microsequence alterations of MMAC1 were detected in 12 (approximately 16%) of the lines, including those derived from astrocytoma, leukemia, and melanoma tumors, as well as bladder, breast, lung, prostate, submaxillary gland, and testis carcinomas. In addition, in this set of tumor cell lines, we detected 11 (approximately 14%) homozygous deletions that eliminated coding portions of MMAC1, a class of abnormality not detected by our methods in primary tumors. These data support the occurrence of inactivating MMAC1 alterations in multiple human cancer types. In addition, we report the discovery of a putative pseudogene of MMAC1 localized on chromosome 9.
Insights
The MMAC1/PTEN gene, a tumor suppressor, shows alterations in various human cancers. Further investigation revealed inactivating mutations and deletions in diverse tumor types, supporting its role in cancer development.
Area of Science:
- Oncology
- Human Genetics
- Molecular Biology
Background:
- The MMAC1/PTEN gene, located at chromosome band 10q23, is a candidate tumor suppressor.
- Sequence alterations in MMAC1/PTEN have been observed in glioma, breast, prostate, and kidney tumors.
Purpose of the Study:
- To investigate the mutational profile of the MMAC1/PTEN gene in a wide range of human cancers.
- To identify allelic losses and sequence alterations at the 10q23 locus in tumor specimens and cell lines.
Main Methods:
- Screening of human tumor specimens and cancer cell lines for 10q23 allelic losses.
- Analysis of MMAC1/PTEN sequence alterations, including missense, splicing, and nonsense mutations.
- Detection of homozygous deletions in tumor cell lines.
Main Results:
- Loss of heterozygosity (LOH) at the MMAC1 locus was found in approximately 50% of examined samples.
- MMAC1 variants were detected in 10% of primary tumors with LOH, with higher frequency in glioblastoma (23%).
- Microsequence alterations (16%) and homozygous deletions (14%) of MMAC1 were identified in tumor cell lines.
Conclusions:
- Inactivating MMAC1/PTEN alterations occur in multiple human cancer types.
- The study identified novel MMAC1 alterations in melanoma and pediatric glioblastomas.
- A putative pseudogene of MMAC1 was discovered on chromosome 9.

